News for Daiichi Sankyo Company, Limited (DSKYF)

Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for ₹11,800 crore. NTK alleges Daiichi Sankyo blocked its 2018 open offer for Fortis Healthcare. Daiichi Sankyo denies these claims. NTK seeks damages and an injunction against Daiichi Sankyo's statements. The next court hearing is scheduled for July 11.

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the Amer

IHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to approximately Rs 11,800 crore. This revision follows Daiichi Sankyo's alleged interference with IHH's bid to acquire a larger stake in Fortis back in 2018. The increased claim accounts for losses and reputational harm, with the next hearing set for July 11.

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ETCompany ParticipantsKentaro Asakura - VP of Corporate...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2024 Q3 earnings call.

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ETCompany ParticipantsKentaro Asakura - VP of...

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ETCompany ParticipantsHiroyuki Okuzawa -...

The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2024 Q2 earnings call.

Global Women’s Health Therapeutics Market to Grow at 4.05% CAGR from 2024-2032, Fueled by Increased Focus on Reproductive Health, Menopause, and Breast...

An increase in the prevalence and misdiagnosis of rare diseases has led to an increase in the sales of orphan drugs....

Advancements and Projections in the Antibody Drug Conjugates Market: Insights, Trends, Opportunities, and Recent Developments...

Alzheimer's Drugs Market Targets Early Intervention to Improve Outcomes and Manage Disease Progression...

Esperion Therapeutics, Inc. (NASDAQ:NASDAQ:ESPR) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ETCompany ParticipantsAlina Venezia - Director of...

The global monoclonal antibodies market is projected to witness substantial growth in the coming years, driven by increasing demand for targeted therapies...

The dynamics of the atopic dermatitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies. The rising...

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between these translated documents and...

Q1 2024 results

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global PARP Inhibitors Market...